Astrana Health (ASTH) On Earnings And Deal Plans Is It A Buying Opportunity
Astrana Health earnings, guidance and acquisition plans come into focus
Astrana Health (ASTH) is back on investor radars after its second quarter 2026 earnings, fresh revenue and net income guidance, and comments about ongoing tuck in acquisitions in key expansion markets.
See our latest analysis for Astrana Health.
Astrana Health's latest guidance and acquisition plans come after a sharp share price pullback, with a 30 day share price return down 23.71%, even though the year to date share price return is up 41.79% and the 1 year total shareholder return is 27.35%. However, 3 and 5 year total shareholder returns remain weak, which suggests recent enthusiasm is still being weighed against a tougher longer term record.
If Astrana Health's recent move has you rethinking where growth might come from next, this is a good moment to scan 43 healthcare AI stocks
The share price reset has reopened the debate around Astrana Health. Do the current earnings, guidance and acquisition plans still offer a favourable trade off between risk and potential reward, or has most of the opportunity already been priced in?
Most Popular Narrative: 28.7% Undervalued
The most followed narrative on Astrana Health pegs fair value at $50.13 per share, compared with the latest close at $35.76. This frames a sizeable valuation gap for investors to assess.
Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention. This positions Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages, likely supporting both revenue growth and sustainable margin expansion over time.
Curious how this value-based care push, full risk exposure, and targeted margin profile come together in the $50 fair value story? The key assumptions sit in the revenue mix shift, earnings compounding, and a future profit multiple that is materially lower than where Astrana Health trades today. The detailed projections show how those ingredients line up against the chosen discount rate and long term contract structure.
Result: Fair Value of $50.13 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to watch for pressure from Medicare and Medicaid reimbursement decisions and the risk that Prospect integration costs erode Astrana Health's margin ambitions.
Find out about the key risks to this Astrana Health narrative.
Another View on Astrana Health valuation
While the most followed Astrana Health narrative leans on detailed earnings projections and a fair value of $50.13, current market ratios tell a different story. The stock trades on a P/E of 43.4x, which is higher than the fair ratio of 36.2x, the US Healthcare industry at 25.3x, and peers at 28.2x. That pricing suggests investors are already paying a premium, so the key question is whether future execution can fully justify it.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Astrana Health, the story is clearly not one sided and there are concerns as well as reasons for optimism. Take a moment to review both angles in detail by checking the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Astrana Health?
Do not stop with Astrana Health. Use this moment to broaden your watchlist with stocks that match the kind of risk and quality profile you actually want.
- Target quality at a fair price by scanning companies that look undervalued on fundamentals using the 51 high quality undervalued stocks
- Focus on resilience by looking at businesses with strong finances through the solid balance sheet and fundamentals stocks screener (49 results)
- Explore under followed opportunities with solid fundamentals using the screener containing 19 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com